Subclinical inflammation, disease relapse and reresponse upon dose increase: An ACCENT I subanalysis

Introduction: We investigated whether ACCENT I patients clinically responding to scheduled infliximab therapy were more likely to experience a future disease relapse if they showed signs of persistent subclinical inflammation, using Creactive protein (CRP) as a marker. We further investigated if response was reestablished upon crossover to a higher dose. Aims & Methods: In ACCENT I, 573 patients with active CD received an infusion of 5mg/kg infliximab and were randomised into an episodic (Group 1) and two infliximab scheduled treatment groups. The scheduled treatment groups received further infusions of 5mg/kg i…